Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
US Stocks Movement: CoreWeave surged on October 19 as Goldman Sachs upgraded its rating, boosted by AI cloud computing power and technology stocks rebound

US Stocks Movement: CoreWeave surged on October 19 as Goldman Sachs upgraded its rating, boosted by AI cloud computing power and technology stocks rebound

Bitget异动解读Bitget异动解读2026/10/19 13:25
Show original

CoreWeave October 19 Surge Interpretation

Keywords: Goldman Sachs rating upgrade, AI cloud computing power, tech stock rebound

1. On October 19, Goldman Sachs upgraded CoreWeave’s rating from “Neutral” to “Buy”; Goldman Sachs believes the market is overly concerned about financing costs and underestimates CoreWeave’s ability to charge for computing power, further projecting that annual revenue per megawatt could rise from $10 million to $13 million.

2. On October 19, Nasdaq 100 Index futures rose over 1%, with tech stocks such as Nvidia and AMD rebounding, and CoreWeave strengthened alongside AI-related stocks.

(Disclaimer: This content is summarized based on publicly available information collected by AI and is for reference only. It does not constitute investment advice.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%

Researchers combined Amgen's Imdelltra with AstraZeneca's Imfinzi and found that for patients with aggressive lung cancer whose tumors had already spread, this combination extended survival by about eight months compared to Imfinzi monotherapy. Small cell lung cancer is one of the cancer types with the worst prognosis.

智通财经•2026/10/25 02:56
Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%